Market research
LHI.F Living Cell Technologies Limited
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.48
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000LCT6
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.48
About
About Living Cell Technologies Limited
Algorae Pharmaceuticals Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. The company was founded in 1987 and is based in Melbourne, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LHI.F discussion.
5 years, 5 months ago
Living Cell Technologies Limited is currently in a long term downtrend where the price is trading 43.1% below its 200 day moving average.
From a valuation standpoint, the stock is 59.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 2091.6.
Finally, its free cash flow grew by 74.6% to $-313K since the same quarter in the previous year.
Based on the above factors, Living Cell Technologies Limited gets an overall score of 1/5.